Upper GI 2017

First line  Doublets or triplets?

Triplets only in patients with high symptom burden Stop using epirubicin

Second line  What should be a standard?

Ramucirumab-paclitaxel PS 0-1; PFS > 3-6 months

 Are all patients candidated to a second line therapy?

Molecular classification  Do we have distinct treatment choices for these different molecular pathways?  How can we address tumor heterogenity when we design GC clinical trials?

Work in progress

Methodological framework Innovative clinical trial designs

03/28/2017